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Abstract
Staphylococcal enterotoxin B (SEB) is one of a family of toxins secreted by Staphylococcus aureus that act as superantigens,
activating a large fraction of the T-cell population and inducing production of high levels of inflammatory cytokines that can
cause toxic shock syndrome (TSS) and death. Extracellular engagement of the TCR of T-cells and class II MHC of antigen
presenting cells by SEB triggers the activation of many intracellular signaling processes. We engineered chimeric antibodies
to block the extracellular engagement of cellular receptors by SEB and used a statin to inhibit intracellular signaling.
Chimeric human-mouse antibodies directed against different neutralizing epitopes of SEB synergistically inhibited its
activation of human T-cells in vitro. In the in vivo model of lethal toxic shock syndrome (TSS) in HLA-DR3 transgenic mice,
two of these antibodies conferred significant partial protection when administered individually, but offered complete
protection in a synergistic manner when given together. Similarly, in vivo, lovastatin alone conferred only partial protection
from TSS similar to single anti-SEB antibodies. However, used in combination with one chimeric neutralizing anti-SEB
antibody, lovastatin provided complete protection against lethal TSS in HLA-DR3 transgenic mice. These experiments
demonstrate that in vivo protection against lethal doses of SEB can be achieved by a statin of proven clinical safety and
chimeric human-mouse antibodies, agents now widely used and known to be of low immunogenicity in human hosts.
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Introduction
Staphylococcal enterotoxin B (SEB) is a potent exotoxin
secreted by Staphylococcus aureus that causes life-threatening toxic
shock syndrome (TSS) [1,2,3,4,5] and food poisoning [6].
Resistant to denaturation, readily produced by recombinant
DNA technology and highly toxic (LD50 in humans estimated to
be nanograms/kg [7,8]), SEB is classified as a priority B
bioterrorism agent. A superantigen, SEB binds to both MHC-II
on antigen presenting cells (APCs) and to TCRs incorporating
particular Vb chains on T-cells [2,3,4,9,10]. The toxin can
activate up to 20% of T-cells resulting in the induction of high
levels of proinflammatory cytokines, including IL-2, IFN-c, and
TNF-b derived from TH1 cells [1,2,3,11,12,13] and IL-1 and
TNF-a from activated APCs [14,15,16]. Its action is initiated by
an extracellular phase in which toxin engages the TCR, thereby
triggering intracellular signal transduction processes that result in
T-cell activation. Several approaches to preventing the formation
of MHC- II/SAg/TCR complexes have been explored and
include induction of anti-SEB antibodies by immunization with
proteosome-SEB toxoid vaccines [17,18], inactivated recombinant
SEB vaccine [19,20,21], and synthetic peptides [22], IVIG for
passive immunoprophylaxis and immunotherapy [23,24,25,26],
peptide antagonists [12,27,28], and synthetic chimerically linked
mimics of SEB-binding regions of class II and TCR [29,30,31].
Engineered mimics of TCR Vb [32] that block SEB activation in
vitro and show promising results when tested in vivo in a rabbit
model have been reported [32]. However, these mimics were
reported to have short half-lives (325 minutes in rabbits) and their
test in human MHC-II transgenics, a robust animal model that
mimics human TSS [33,34,35,36,37,38] has not yet been
reported. Despite these efforts, at present there is no curative
treatment for SEB-induced TSS, no practical prophylaxis and no
antidote for intoxication following accidental or malicious
exposure. The mortality rate varies from 4 to 22% and clinical
treatment is currently focused on supportive measures, targeted
antibiotic therapy, and adjunctive immunomodulatory therapy
[39].
We recently generated high affinity human-mouse chimeric
monoclonal antibodies (MAbs) against SEB. We have shown that
these antibodies are capable of neutralizing SEB in vitro,a n d
attenuate SEB-induced immune activation in vitro [40]. Subsequent
to our report, there have been studies describing the generation of
additional anti-SEB antibodies [41,42]. More recently, Varshney
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monoclonal antibodies with neutralizing and protective abilities
against SEB-induced lethal shock (SEBILS) [43]. In the current
study we establish the neutralizing potential of our human-mouse
chimeric antibodies in vivo and also showthat our chimeric anti-SEB
antibodies are able to protect from lethal SEB-induced TSS in a
more robust HLA-DR3 transgenic mice model. In addition, we
examined the possibility that an intracellular inhibitor of T-cell
activation and cytokine signaling would complement the inhibitory
effectof extracellularly actinganti-SEBantibody. As anintracellular
inhibitor of SEB-induced signal transduction processes, we used
lovastatin,and found this statininhibited T-cell activation just as the
structurally similar simvastatin has been shown to do [44].
Lovastatin (Mevacor
TM) is widely used in clinical practice and is
known to have low toxicity in humans [45]. In addition to their well
known role in reduction of cholesterol levels, statins are known also
to have anti-inflammatory and immunomodulatory properties
[44,46]. Simvastatin is reported to inhibit SEB-mediated T-cell
activation in human peripheral blood [44], and atorvastatin
enhances T-cell differentiation from TH1t oT H2 [47]. Statins also
inhibit cytokine-mediated signaling pathways [48].
Results
Chimeric Anti-SEB Antibodies Protect Mice from SEB-
induced TSS More Effectively in Combination than Alone
In our previous report, we identified a pair of high affinity, non-
crossreacting, and SEB-neutralizing mouse MAbs and then
converted these antibodies into the mouse-human chimeric
antibodies, Ch 82 M and Ch 63 [40]. When we tested the SEB-
neutralization efficiency of these chimeric antibodies in vitro in
splenocyte cultures derived from HLA-DR3 transgenic nice, a
more demanding and humanlike model system [35,36,37,49] as
well as in human PBMCs, a combination of Ch 82 M and Ch 63
produced a greater neutralization of SEB than equivalent amounts
of either 82 M or Ch 63 acting alone [40].
SEB binds human MHC-II more strongly than mouse [11,50].
Rajagopalan [36,37] and others [35,49] have shown that HLA-
DR3 transgenic mice, engineered to express human instead of
mouse class II MHC, provide a more stringent model system for
the exploration and development of anti-SEB strategies than
conventional mice. Moreover, unlike the conventional animal
models, HLA-DR3 transgenic mice do not require sensitizing
agents to induce TSS with SEB. Challenging naı ¨ve HLA-DR3
transgenic mice with 50 mg of SEB causes them to undergo a rapid
and sharp drop in body temperature (hypothermia), produce an
excess amount of inflammatory cytokines and die within 7 days.
The immunopathogenesis of TSS in HLA-DR3 transgenic mice
more closely mimics the human disease [33,35]. Therefore, we
performed in vivo studies in HLA-DR3 transgenic mice to examine
the efficacy of these chimeric antibodies in protecting mice from
SEB-induced excessive systemic cytokine production, TSS symp-
toms and lethality.
We challenged HLA-DR3 transgenic mice with SEB alone, or
SEB along with chimeric anti-SEB or human IgG1k isotype
control antibody. We monitored the body temperature of the
mice for 24 hours by recording rectal temperature at the
indicated time points. While either Ch 82 M or Ch 63
significantly decreased (P,0.05) hypothermia, mice treated with
an equivalent amount of an equimolar mixture of Ch 82 M plus
Ch 63, experienced no drop in temperature 6 hours after SEB
administration indicating the synergistic effect of the two
antibodies (P,0.01; Fig. 1A). On the other hand, the body
temperatures of SEB challenged mice treated with PBS or human
IgG1k isotype control fell abruptly in the first 6 hours and
remained below normal for 24 hrs (Fig. 1A).
We next investigated the effect of our chimeric antibodies on
SEB-induced systemic cytokine induction. Since interleukin- 2
(IL-2), and particularly interferon-c (IFN-c), play major roles in
SEB-induced toxic shock syndrome in HLA-DR3 transgenic
mice [33], these cytokines were chosen. Mice injected with SEB
alone, SEB+Chimeric anti-SEB MAbs, or untreated control were
bled 6 hours after injection and serum levels of IL-2, IFN-c and
interleukin- 6 (IL-6) were determined by Bioplex ELISA. Naı ¨ve
HLA-DR3 transgenic mice had undetectable levels of IL-2, IFN-
c and IL-6, whereas mice challenged with SEB alone resulted in
a significant elevation of these cytokines a few hours after
injection of SEB, indicative of the acute course of SEB-induced
TSS. When separately administered, however, either Ch 82 M
or Ch 63 alone significantly reduced SEB-induced production of
IL-2, IFN-c and IL-6 (P,0.01). However, an equivalent amount
of the combination of Ch 82 M+Ch 63 provided a greater
reduction of cytokine secretion (P,0.05) compared with either
antibody alone, reducing cytokines levels that did not signifi-
cantly differ (P.0.05) from those of mice that received no SEB
(Fig. 1B–D). Activity of HLA-DR3 transgenic mice was
monitored after injection of 50 mg of SEB in PBS, or with
chimeric anti-SEB antibodies. After 6 hours, mice treated with
SEB alone were hypothermic, shivered, had hunched posture,
were inactive or unable to move around and had rough coats.
On the other hand, mice treated with 50 mgS E B +500 mgC h
82 M+500 mg Ch 63 appeared normal, were sleek of coat,
energetic and mobile (Fig. 1E).
We then monitored mice treated with SEB alone, or SEB along
with chimeric or isotype control antibodies for a period of 7 days
to record the lethal effect of SEB. Notably, 66% of the mice
receiving a fatal dose of SEB survived if treated with either Ch
82 M or Ch 63 and all mice treated with equivalent amounts of
the combination of Ch 82 M plus Ch 63 survived (100%), whereas
mice that were injected with SEB alone or SEB plus nonspecific
control human IgG1k, all succumbed to SEB toxicity (Fig. 1F).
Treatment with a combination of Ch 82 M and Ch 63 provided
statistically significant (P,0.001) protection against SEB-induced
death.
Effect of Lovastatin on Reducing SEB-induced T-cell
Proliferation In Vitro and its Synergy with Chimeric Anti-
SEB Antibody
The ability of lovastatin to inhibit SEB-induced T-cell
proliferation was examined in vitro in BALB/c and HLA-DR3
transgenic mice splenocytes and human PBMC cultures. The
results of the experiments revealed that lovastatin neutralized SEB-
induced T-cell proliferation significantly (P,0.01) compared to
cells treated with SEB alone (Fig. 2A–C). To confirm the
likelihood that the inhibitory effect of lovastatin is due to its effect
on HMG-CoA reductase, the enzyme targeted by statins, we
added mevalonate, the product of HMG-CoA reductase, to
determine if it reversed the effects of lovastatin. The result
demonstrates the ability of mevalonate to counter the protective
effect of lovastatin and indicates that the inhibitory effect of this
statin on SEB-mediated T-cell activation strongly impacts the
mevalonate pathway (Fig. 2D).
Further in vitro experiments revealed that combinations of Ch
82 M and lovastatin caused a greater reduction of SEB-induced T-
cell proliferation (P,0.01) than either treatment alone in mouse
splenocyte cultures (Fig. 3A), in HLA-DR3 transgenic mice
splenocyte cultures (Fig. 3B), and in human PBMCs (Fig. 3C).
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Lovastatin Protect HLA-DR3 Transgenic Mice from SEB-
induced TSS Better than Either Agent Alone
Since our in vitro experiments demonstrated efficient neutrali-
zation of SEB-induced T-cell activation by a combination of
chimeric anti-SEB, (an extracellular inhibitor), and lovastatin (an
intracellular inhibitor), we examined the possibility of translating
our in vitro SEB neutralization findings into in vivo protection
against SEB-mediated illness and mortality. Similar to the above
experiment using a combination of two chimeric anti-SEB
antibodies, the possibility of cooperative or synergistic inhibition
of SEB action in vivo by anti-SEB antibody and lovastatin was
investigated in the HLA- DR3 transgenic mice TSS model. We
evaluated the effect of these agents on SEB-mediated hypother-
mia, serum cytokine (IL-2, IFN-c, and IL-6) levels and mortality.
Figure 4A shows that 6 hours after SEB administration, the
combination of Ch 82 M and lovastatin was superior to Ch 82 M
or lovastatin alone (P,0.05) in ameliorating hypothermia.
Although Ch 82 M or lovastatin inhibited IL-2 accumulation as
well as that of the inflammatory cytokines IFN-c and IL-6,
combinations of Ch 82 and lovastatin were more effective than
either agent alone (P,0.01) in inhibiting SEB-induced cytokine
production (Fig. 4B-D). Most importantly, combination of Ch
82 M and lovastatin conferred full protection against SEB
mediated death, where as Ch 82 M conferred 66% protection,
lovastatin conferred 50% protection and all mice that did not
receive treatment were victims of SEB lethality (Fig. 4E).
Treatment with a combination of Ch 82 M and lovastatin
conferred statistically significant (P,0.01) protection against
SEB-induced death.
Discussion
SEB-mediated diseases are the result of the activation of a large
subset of the T-cell population. When the SEB crosslinks the MHC
class II of the APCs to the Vb TCR of T-cells to formMHC II-SEB-
TCR complexes, it results in the activation of T-cells and induction
of massive systemic release of inflammatory cytokines. Hence,
blockade of SEB binding to either receptor prevents formation of the
MHC II-SEB-TCR complex and inhibits the superantigenic action
of SEB. Therefore, therapeutic approaches targeting disruption of
MHC II-SEB-TCR complex formation at an early stage of the
pathogenic process could prevent, minimize, or ameliorate the
severityand incidenceofSAg-caused diseases.Inthisreport,weused
anti-SEB antibodies reported previously [40] to prevent binding of
SEB to its receptors and showed that they were able to efficiently
neutralize SEB-induced proinflammatory cytokine production in
vivo, and prevent SEB-mediated disease and death in an HLA-DR3
transgenic animal model. Our findings demonstrated the synergistic
actionofthetwoantibodiesinneutralizingSEB-mediatedTSSinvivo
in a readily available and robust animal model. These findings
encourage the further evaluation of these approaches for the
treatment and prevention of TSS in humans.
Given the rapidity with which SEB causes T-cell activation and
elicits cytokine/chemokine production in vivo, relying only on
Figure 1. Chimeric anti-SEB 82 M and 63 synergistically protect HLA-DR3 mice from the toxic effects of SEB. (A) Protection against SEB-
induced hypothermia. Age-matched HLA-DR3 transgenic mice were injected with the following: Ch 82 M+Ch 63+SEB (¤), 500 mg chimeric
82 M+500 mg chimeric 63+50 mg SEB; Ch 63+SEB (&), 1 mg chimeric 63+50 mg SEB; Ch 82 M+SEB (m),1 mg chimeric 82 M+50 mg SEB; Hu IgG1k+SEB
(6), 1 mg human IgG1k+50 mg SEB; SEB alone (*); 50 mg SEB in PBS. Rectal temperatures were recorded at the indicated time points. Error bars are
the means 6 s.d. for each group, and the data shown are representative of two or more independent experiments. (B–D) Inhibition of SEB-induced
cytokine production. Serum levels of interleukin-2 (B), interferon-c (C), and interleukin-6 (D) were determined at 6 hours post-SEB injection in groups
of age-matched HLA-DR3 transgenic mice treated with the following: naı ¨ve, PBS only; Ch 82 M+SEB, 1 mg Ch 82 M+50 mg SEB; Ch 63+SEB, 1 mg Ch
63+50 mg SEB; Ch 82 M+Ch 63+SEB, 500 mgC h8 2M +500 mgC h6 3 +50 mg SEB; SEB alone, 50 mg of SEB in PBS. Differences between the combination
of anti-SEBs and either antibody used alone were significant (P,0.05) in inhibiting SEB-induced cytokine production. Each bar represents the means
6 s.d. for each group, and the data shown are representative of two or more independent experiments. (E) Appearance of mice protected with anti-
SEB and unprotected mice 6 hours after a 50 mg dose of SEB. The mouse on the left received no protective antibody, suffered hyperthermia, shivered
and displayed hunched posture and a rough coat. The mice on the right, which were treated with 50 mg SEB+500 mgC h8 2M +500 mgC h6 3
appeared normal, were sleek of coat and animated. (F) Protection against SEB-mediated death. Survival was monitored within groups of age-
matched HLA-DR3 transgenic mice receiving the following: SEB alone, 50 mg SEB in PBS; Hu IgG1k+SEB, 1 mg human IgG1k+50 mg SEB; Ch
82 M+SEB, 1 mg Ch 82 M+50 mg SEB; Ch 63+SEB, 1 mg Ch 63+50 mg SEB; Ch 82 M+Ch 63+SEB, 500 mgC h8 2M +500 mgC h6 3 +50 mg SEB.
Combination of Ch 82 M and Ch 63 provided statistically significant protection (P,0.001) against SEB-induced death compared with untreated
controls. The data shown are representative of two or more independent experiments.
doi:10.1371/journal.pone.0027203.g001
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inhibiting independent processes essential for SEB-mediated T-cell
activation. We tested the hypothesis that a multipronged attack
aimed at disrupting the formation of MHC II-SEB-TCR complex,
an approach inhibiting the signaling events elicited in T-cells (and
APC) following this interaction as well as inhibiting the
downstream signaling events in target tissues/cells in response to
the systemic cytokine/chemokine storm elicited by SEB, would be
more effective. Given the known immunomodulatory functions of
statins and their established ability to inhibit T-cell as well as
cytokine/chemokine signaling, we evaluated lovastatin in this
study. Although identifying all of the molecular mechanisms by
Figure 2. Neutralization of SEB-induced T-cell proliferation by lovastatin. (A) In vitro neutralization in BALB/c splenocytes. BALB/c
splenocytes (56105 cells/well) were incubated at 37uC for 48 hours in the presence of medium alone, SEB alone (100 ng/ml), SEB+different
concentrations of lovastatin (0.625 mM, 1.25 mM, and 2.5 mM) as indicated. Cells were then pulsed with 3H-thymidine (1 mci/well), incubated for an
additional 18 hours, harvested and cell proliferation determined by measuring 3H-thymidine incorporation. Each bar represents the means 6 s.d. of
triplicate measurements, and the data shown are representative of two or more independent experiments. Neutralization of SEB-induced T-cell
proliferation by lovastatin were significant (P,0.01) compared with results obtained with SEB alone. (B) SEB neutralization in HLA-DR3 transgenic
mice splenocytes. HLA-DR3 splenocytes (56105 cells/well) were incubated at 37uC for 48 hours in the presence of medium alone, with various
concentration of SEB alone (10 ng/ml and 1 ng/ml), or SEB plus lovastatin (2.5 mM). Cells were then pulsed with 3H-thymidine (1 mci/well), incubated
for an additional 18 hours, harvested and cell proliferation determined by measuring 3H-thymidine incorporation. Each bar represents the means 6
s.d. of triplicate measurements, and the data shown are representative of two or more independent experiments. Neutralization of SEB-induced T-cell
proliferation by lovastatin were significant (P,0.01) compared to cells treated with SEB alone. (C) SEB neutralization in human PBMC. Human PBMC
(56105 cells/well) were incubated at 37uC for 48 hours in the presence of medium alone, SEB alone (1 ng/ml), or SEB plus lovastatin (2.5 mM). Cells
were then pulsed with 3H-thymidine (1 mci/well), incubated for an additional 18 hours, harvested and cell proliferation determined by measuring 3H-
thymidine incorporation. Each bar represents the means 6 s.d. of triplicate measurements, and the data shown are representative of two or more
independent experiments. Neutralization of SEB-induced T-cell proliferation by lovastatin were significant (P,0.01) compared to cells treated with
SEB alone. (D) Mevalonate mediated reversal of lovastatin’s inhibition of SEB in BALB/c splenocytes. Bar groups are organized by the amount of
mevalonate added to each well. BALB/c splenocytes (56105 cells/well) were incubated at 37uC for 48 hours with various concentration of mevalonate
(25 mM, 250 mM, 25 mM or 0), and in the presence of SEB alone (100 ng/ml SEB); lovastatin+SEB (2.5 mM lovastatin+100 ng/ml SEB); Ch 82 M+SEB
(10 mg/ml chimeric anti-SEB 82 M+100 ng/ml SEB); IgG1k+SEB (10 mg/ml human IgG1k isotype control+100 ng/ml SEB). Cells were then pulsed with
3H-thymidine (1 mci/well), incubated for an additional 18 hours, harvested and cell proliferation determined by measuring 3H-thymidine
incorporation. Each bar represents the means 6 s.d. of triplicate measurements, and the data shown are representative of two or more independent
experiments. Inhibition of SEB by lovastatin was not significant (P.0.05) at 25 mM mevalonate.
doi:10.1371/journal.pone.0027203.g002
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cytokine/chemokine signaling is difficult and would require
further investigation, some of the possible explanations can be
deduced from work reported in the literature.
Lovastatin (Mevacor
TM) is a widely prescribed drug for
treatment of hypercholesterolemia. Recent studies indicate that
statins also have anti-inflammatory and immunomodulatory
functions [44,46]. Affecting intracellular processes, statins de-
crease IFN-c-induced expression of MHC class II on APCs [51],
blocks the interaction between LFA-1 on APC and ICAM-1
expressed on T- cells [52], and decreases HLA-DR and CD38
expression on T-cells [44]. MHC class II expression on APCs is
important for SEB to bind as its primary target receptor and to
crosslink it to T-cells expressing Vb TCR to form a complex and
Figure 3. Synergistic neutralization /inhibition of SEB-mediated T-cell activation by a combination of anti-SEB antibody and
lovastatin. (A) Anti-SEB Ch 82 M and lovastatin inhibit SEB action in BALB/c splenocytes. BALB/c splenocytes were cultured as outlined in materials
and methods with the following additives: Medium alone, SEB alone, 100 ng/ml SEB; Hu IgG1k+SEB, 10 mg/ml Human IgG1k+100 ng/ml of SEB; Ch
82 M+SEB, 10 mg/ml chimeric anti-SEB 82 M+100 ng/ml SEB; Lova+SEB, 2.5 mM lovastatin+100 ng/ml SEB; Ch 82 M+Lova+SEB, 10 mg /ml chimeric
anti-SEB 82 M+2.5 mM lovastatin+100 ng/ml SEB. Each bar represents the means 6 s.d. of triplicate measurements, and the data shown are
representative of two or more independent experiments. The combination of Ch 82 M+lovastatin was significantly more inhibitory than either agent
alone (P,0.01). (B) Anti-SEB Ch 82 M and lovastatin inhibit SEB action in HLA-DR3 transgenic mice splenocytes. HLA-DR3 transgenic mice splenocytes
were cultured as outlined in materials and methods with the following additives: Medium alone, SEB alone, 10 ng/ml SEB; HuIgG1k+SEB, 10 mg/ml
Human IgG1k+10 ng/ml of SEB; Ch 82 M+SEB, 10 mg/ml chimeric anti-SEB 82 M+10 ng/ml SEB; Lova+SEB, 2.5 mM lovastatin+10 ng/ml SEB; Ch
82 M+Lova+SEB, 10 mg/ml chimeric anti-SEB 82 M+2.5 mM lovastatin+10 ng/ml SEB. Each bar represents the means 6 s.d. of triplicate measurements,
and the data shown are representative of two or more independent experiments. The combination of Ch 82 M and lovastatin was significantly more
inhibitory than either agent alone (P,0.01). (C) Anti-SEB Ch 82 M and lovastatin inhibit SEB action in human PBMCs. PBMCs were cultured as outlined
in materials and methods with the following additives: Medium alone, SEB alone, 1 ng/ml SEB; HuIgG1k+SEB, 10 mg/ml Human IgG1k+1 ng/ml of
SEB; Ch 82 M+SEB, 10 mg/ml chimeric anti-SEB 82 M+1 ng/ml SEB; Lova+SEB, 2.5 mM lovastatin+1 ng/ml SEB; Ch 82 M+Lova+SEB, 10 mg/ml chimeric
anti-SEB 82 M+2.5 mM lovastatin+1 ng/ml SEB. Each bar represents the means 6 s.d. of triplicate measurements, and the data shown are
representative of two or more independent experiments. The combination of Ch 82 M and lovastatin was significantly more inhibitory than either
agent alone (P,0.01).
doi:10.1371/journal.pone.0027203.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27203induce T-cell activation. A statin-mediated decrease in the
expression of MHC class II would ultimately decrease the
number of MHC II –SEB-TCR complexes formed and lower the
number of T-cells activated. Similarly, LFA-1, ICAM-1 interac-
tion is required for SEB-induced TSS [53]. The effect of another
statin, simvastatin in inhibiting SEB-mediated T-cell activation in
cultures of human PBMC, may be related to inhibition of LFA-1
[44]. Therefore, given the significance of APC-T-cell interaction
pathways in activation by SEB, lovastatin could antagonize the
effects of SEB by inhibiting this interaction. In addition, statins
are known to promote a TH1t o T H2 polarization [47]. Such
a mechanism could ameliorate the severity of TSS since
SEB-induced pathology is thought to be caused by the proin-
flammatory cytokine storm derived mainly from TH1 cells
[1,2,3,11,12,13].
In addition to its effect on T-cells, statins could mediate its anti-
inflammatory effect on the innate immune system by inhibiting
pro-inflammatory signals from many cytokines and chemokines
that are produced during TSS [48]. Taken together, all of these
effects suggest that statins have the potential to inhibit TSS by a
variety of mechanisms. Consistent with our laboratory findings,
retrospective human studies have shown that patients who were
previously taking statins had better outcomes following sepsis or
trauma [54].
Given the widespread use of chimeric antibodies in human
patients to treat a variety of clinical conditions and the fact that
lovastatin has been in clinical use in humans for many years, our
suggestion of a therapeutic approach incorporating these agents
would be expected to be well-tolerated in clinical settings and, may
be suitable for widespread administration to populations under
threat of malevolent use of SEB. Looking beyond biodefense, SEB
is known to be produced during many Staphylococcus aureus
infections in vivo. Given that S. aureus is the leading cause of
infections in hospitalized patients [55], exploration of the clinical
use of our antibodies either alone or in combination with lovasatin
or other immunomodulatory agents, is worthy of consideration.
Therefore, incorporating a well tolerated inhibitor of the
intracellular processes necessary for the action of superantigens,
such as lovastatin, encourages investigation of its use in
combination therapies for the prophylaxis and therapy of disease
caused by clinically significant representatives of these bacterial
toxins. Also, the derivation and chimerization of neutralizing
antibodies against other staphylococcal (and streptococcal) super-
antigen toxins is quite feasible. Once produced, they can be added
to those reported here to provide a polyclonal mixture of anti-
toxin antibodies, a combination broadly protective against a
variety of these superantigens and likely to be synergistically active
with agents such as lovastatin.
Figure 4. Chimeric anti-SEB 82M and lovastain provide in vivo protection against SEB toxicity in HLA-DR3 transgenic mice. (A)
Inhibition of SEB-mediated hypothermic effect. Age-matched HLA-DR3 transgenic mice were injected with the following: Ch 82 M+Lova+SEB (¤),
1 mg chimeric 82 M+1 mg lovastatin+50 mg SEB; Ch 82 M+SEB (&), 1 mg chimeric 82 M+50 mg SEB; Lova+SEB (m), 1 mg lovastatin +50 mg SEB; SEB
alone (6), 50 mg SEB in PBS. Rectal temperatures were recorded at the indicated time points. Error bars are the means 6 s.d. for each group, and the
data shown are representative of two or more independent experiments. (B–D) Inhibition of SEB-induced cytokine production. Serum levels of
interleukin-2 (B), interferon-c (C) and interleukin-6 (D) were determined at 6 hours post-SEB injection in groups of age-matched HLA-DR3 transgenic
mice treated with the following: naı ¨ve, PBS only; Ch 82 M + SEB, 1 mg Ch 82 M+50 mg SEB; Lova + SEB, 1 mg lovastatin +50 mg SEB; Ch 82 M + Lova +
SEB, 1 mg Ch 82 M+1 mg lovastatin+50 mg SEB; SEB alone, 50 mg SEB in PBS. Differences between the combination of Ch 82 M and lovastatin and
either drug or antibody alone were significant (P,0.05) in inhibiting SEB-induced cytokine production. Each bar represents the means 6 s.d. for each
group, and the data shown are representative of two or more independent experiments. (E) Protection against SEB-mediated death. Survival was
monitored within groups of age-matched HLA-DR3 transgenic mice receiving the following: SEB alone, 50 mg SEB in PBS; Ch 82+SEB, 1 mg of Ch
82 M+50 mg SEB; Lova+SEB, 1 mg of lovastatin+50 mg SEB; Ch 82 M+Lova + SEB, 1 mg Ch 82 M+1 mg lovastatin+50 mg SEB. Survival was monitored
for 7 days. Combination of Ch 82M and lovastatin provided statistically significant protection (P,0.01) against SEB-induced death compared with
mice treated with SEB alone. The data shown are representative of two or more independent experiments.
doi:10.1371/journal.pone.0027203.g004
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Ethics Statement
All animal experimentation was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use
Committee of Mayo Clinic (Approval number: A26408, A29507
and A31810). The AAALAC Accreditation Number is 000717
and the OLAW Assurance Number is A3291-01. All efforts were
made to minimize suffering.
Mice
BALB/c (H-2
d) or HLA-DRB1*0301 mice were sources of
splenocytes for some in vitro neutralization studies. HLA-DR3
transgenic mice expressing functional HLA-DRA1*0101 and
HLA-DRB1*0301 transgenes on a completely mouse MHC-II-
deficient background (AE
0) were generated as described elsewhere
[36,56,57].
SEB
Endotoxin-reduced SEB was purchased from Toxin Technol-
ogy (Sarasota, FL), and laboratory stocks were always less than the
federally mandated limit of 5 mg. The manufacturer has certified
that the SEB batch purchased has.95% purity on the basis of gel
analysis. In house SDS-PAGE confirmed the purity of SEB.
In Vitro SEB Neutralization
Splenic mononuclear cells from BALB/c or HLA- DR3
transgenic mice were isolated by Ficoll-Paque Plus (GE Health-
care, Uppsala, Sweden) gradient centrifugation and washed 2X
with PBS and resuspended in growth medium (RDGS) containing
45% DMEM, 45% RPMI 1640, 10% fetal bovine serum (FBS),
55 mM 2ME (all from Invitrogen, Carlsbad, CA), and 20 mg/ml
gentamicin (Sigma-Aldrich, St. Louis, MO). Human PBMCs were
purchased from Stem Cell Technologies (Vancouver, Canada).
Cell suspensions (5610
6 cells/ml) were distributed in 100 ml
aliquots to the wells of 96-well flat-bottom plates (5610
5 cells/well)
containing 50 ml of various concentrations of SEB and 50 ml of the
indicated concentration of anti-SEB antibody and/or the
indicated concentration of lovastatin. Each condition was run in
triplicate. The cells were incubated (at 37uC in 7.5% CO2) for
48 hours and then pulsed with 1 mCi
3H- thymidine (Amersham/
GE Healthcare) per well, incubated an additional 18 hours and
then harvested onto glass fiber filter strips with a PhD cell
harvester (Brandel, Gaithersburg, MD). The incorporated radio-
activity was measured by liquid scintillation counting and
stimulation indices (SI) were calculated as;
SI~
Average net CPM from SEB treated cultures
Average net CPM of untreated cultures
In Vivo TSS Study
Age-matched HLA-DR3 transgenic mice were challenged with
50 mg SEB in PBS by the intraperitoneal(i.p.) route immediately
following injection of the indicated treatments of PBS, isotype
control (human IgG1k), chimeric anti-SEB antibodies (Ch 63 and
Ch 82 M), and/or lovastatin. Body temperatures and survival
were determined at the indicated time intervals. Blood samples
collected at 6 hrs after the indicated treatment were tested
according to the manufacturers’ instructions in a Bio-plex cytokine
ELISA (Bio-Rad Laboratories, Hercules, CA) to determine the
serum levels of IL-2, IFN-c and IL-6.
Statistical Methods
Mean values of stimulation index (SI), body temperature, and
cytokine levels were compared using Student’s t test with P
values,0.05 considered significant. Survival curves and their
statistical analysis were generated using the GraphPad Prism
software (version 5.0d; San Diego, CA).
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